17.01.2013 13:35 Uhr, Quelle: Wallstreet online

Alimera Sciences´ ILUVIEN® Receives Marketing Authorization In Spain For The Treatment Of Chronic Diabetic Macular Edema

ATLANTA, Jan. 17, 2013 /PRNewswire/ Alimera Sciences, Inc., (Alimera), a biopharmaceutical company that specializes in the research, development and commercialization of prescription ophthalmic pharmaceuticals, today announced the Spanish …

Weiterlesen bei Wallstreet online

Digg del.icio.us Facebook email MySpace Technorati Twitter

JustMac.info © Thomas Lohner - Impressum - Datenschutz